Goldman Sachs Initiates Coverage On Halozyme Therapeutics with Buy Rating, Announces $24 Price Target

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Buy rating and a $24 price target.

Benzinga · 01/08/2020 11:45

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Buy rating and a $24 price target.